에 대한 최신 뉴스 ESS Tech (NYSE:GWH) 주식

ESS Tech

ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.

ESS Tech Inc

Global Wholehealth Partners Corp

JMP Securities analyst Reni Benjamin reiterates Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Market Outperform and maintains $40 price target.

News

Price Target

Reiteration

Analyst Ratings

SMMT

JMP Securities Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target

When discount retailer Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) reports its first-quarter financial results Tuesday before the market opens, it could provide a look at consumer spending trends <a href="https://www.benzinga.com/topic/tariffs">and overall tariff impacts</a>.
Here are the analyst estimates for the quarter, analyst commentary ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Dollar General to report first-quarter revenue of $10.31 billion. That&#8217;s up from $9.91 billion in last year's first quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0602"> from Benzinga Pro.</a>
The company has beaten analyst revenue estimates for two straight quarters and in five of the last six quarters.
Analysts expect Dollar General to report first-quarter earnings per share of $1.48, down from $1.65 in last year's first quarter. The company has beaten analyst estimates for earnings per share in only four of the last 10 quarters overall.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45719780/how-to-earn-500-a-month-from-dollar-general-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Dollar General Stock Ahead Of Q1 Earnings</a>
What Analysts Are Saying: Bank of America Securities analyst Robert F. Ohmes said in a recent note that Dollar General could report a surprising acceleration in the quarter<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45592921/dollar-general-set-for-q1-analyst-sees-trade-in-momentum-margin-recovery-strong-price-gaps-over-rivals">.</a>
The analyst reiterated a Buy rating and raised the price target from $100 to $115.
Ohmes expects Dollar General to report comp sales up 1% year over year, with a real-time data acceleration.
Items like store remodel costs, higher labor costs, and store closure costs could affect the quarter&#8217;s earnings per share results.
According to Ohmes, digital expansion, a DoorDash Inc partnership and first-party offerings could support sales momentum in the quarter.
Here are other<a href="https://www.benzinga.com/quote/DG/analyst-ratings"> recent analyst ratings </a>on Dollar General and their price targets:
<ul class="wp-block-list">
<li>UBS: Maintained Buy rating, raised price target from $90 to $125</li>
<li>Telsey: Maintained Market Perform rating, raised price target from $85 to $100</li>
<li>Goldman Sachs: Maintained Buy rating, raised price target from $85 to $96</li>
<li>Morgan Stanley: Maintained Equal Weight rating, raised price target from $80 to $85</li>
</ul>
Key Items to Watch: Like many other recent quarterly reports from retailers, investors and analysts will be looking for commentary on tariffs. Whether there is an impact on financial results remains to be seen.
Dollar General will likely highlight what it's doing to help offset the impact of tariffs and maintain current prices.
Dollar General saw same-store sales up 1.2% year-over-year in <a href="https://www.benzinga.com/25/03/44300130/dollar-general-q4-revenue-crushes-estimate-as-sales-in-new-stores-pick-up">the fourth quarter, </a>helped by an increase in the average transaction amount.
A Placer.ai <a href="https://www.placer.ai/anchor/articles/dollar-stores-stability-in-the-new-year">report </a>showed that Dollar General saw visits up 1.9% year-over-year. This included a 6.6% increase in January and 1.0% increase in March with a -1.5% drop in visits in February. The monthly data was lower than Dollar Tree visits, which could be an item to watch for potential market share loss.
Guidance will also be key with some retailers pulling guidance due to tariffs and macroeconomic concerns. The Placer.ai report showed Dollar General April visits up 6.5% year-over-year.
Dollar General&#8217;s quarterly results will come one day before rival Dollar Tree Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) reports its own results. Investors will have two reports from discount retailers to help gauge the impact of tariffs.
Dollar Tree — known for items priced $1, or $1.25 now thanks to recent inflation — warned consumers about higher prices due to tariffs.
Other retailers, like Walmart, have <a href="https://www.benzinga.com/markets/25/05/45536218/walmart-responds-to-trumps-eat-the-tariff-remark-worked-to-keep-our-prices-as-low-as-possible-and-we-wont-stop">alerted customers of rising prices</a>, drawing the ire of President Donald Trump.
DG Price Action: Dollar General stock is down 0.09% to $97.16 on Monday versus a 52-week trading range of $66.43 to $141.24. Dollar General stock is up 29.6% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45527616/marjorie-taylor-greene-goes-shopping-for-tesla-netflix-unitedhealth-stock-here-are-the-latest-19-stocks-bought">Marjorie Taylor Greene Goes Shopping For Tesla, Netflix, UnitedHealth And More: 19 Stocks The Congresswoman Bought</a></li>
</ul>
Image: Shutterstock

Previews

Trading Ideas

DLTR

Dollar General Q1 Earnings Preview: Could Tariffs Hit Discount Retail Hardest?

WIIM

CETX

Cemtrex shares are trading higher after the company announced it received $0.8 miillion in contracts from UK Correctional Facilities.

Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) stock is trading lower on Monday amid reports indicating <a target="_blank" href="https://www.benzinga.com/topic/donald-trump" rel="noreferrer noopener">the Trump administration</a> is widening its spending review beyond consulting firms&nbsp;to include tech companies.
The General Services Administration on Wednesday wrote to 10 technology providers, including Dell and CDW Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>) urging them to justify their work and find areas to cut.
The letter highlighted the need to put a tab on the U.S. spending $82 billion annually on IT products and services that have taken a toll on the taxpayer in the form of higher markups, the Wall Street Journal <a href="https://www.wsj.com/business/trump-federal-contracts-tech-firms-c839fdbb?mod=Searchresults_pos5&amp;page=1" target="_blank" rel="noreferrer noopener">reported</a> on Saturday, citing Josh Gruenbaum, commissioner of GSA&#8217;s Federal Acquisition Service&#8217;s letter.
Also Read: <a href="https://www.benzinga.com/news/contracts/25/05/45702431/palantir-stock-gains-as-trump-expands-companys-role-in-us-government-agencies" target="_blank" rel="noreferrer noopener">Palantir Stock Gains As Trump Expands Company&#8217;s Role in US Government Agencies</a>
The Trump administration&#8217;s review of contracts prompted companies like Booz Allen Hamilton Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) to downsize their workforce. 
The Wall Street Journal cited unnamed sources familiar with the matter as stating that since January, the federal government has canceled 11,297 contracts across 60 agencies, leading to $33 billion in overall savings.
The government has halted 2,809 consulting-specific contracts to date.
In February, Defense Secretary Pete Hegseth <a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch" target="_blank" rel="noreferrer noopener">urged senior officials</a> to develop plans to cut 8% of the defense budget each of the next five years. 
<a href="https://www.benzinga.com/markets/25/04/44882365/trumps-energy-department-mulls-cutting-billions-in-clean-energy-funds-threatening-exxon-occidental-projects" target="_blank" rel="noreferrer noopener">April reports indicated</a> the Energy Department is exploring substantial reductions, potentially halting nearly $10 billion in federal funding for clean-energy projects.
An analysis of <a href="https://www.benzinga.com/markets/25/02/43972234/trump-and-elon-musks-cost-cutting-measures-fail-to-curb-rising-us-government-spending-report" target="_blank" rel="noreferrer noopener">federal data reportedly</a> revealed that the U.S. government&#8217;s spending continues to rise despite the Trump administration&#8217;s concerted efforts to cut costs. Between Jan. 21 and Feb. 20, government spending totaled approximately $710 billion, marking a notable increase from the roughly $630 billion spent during the same period last year. This increase is driven by an aging population and an increasing debt burden.
Former Treasury Secretary Larry Summers <a href="https://www.benzinga.com/government/regulations/25/04/44943149/larry-summers-warns-trumps-irs-cuts-could-cost-americans-1-trillion-over-10-years-calls-strategy-raw-incompetence" target="_blank" rel="noreferrer noopener">said that the</a> Trump administration&#8217;s cuts to the Internal Revenue Service (IRS) could result in a $1 trillion government loss.
Price Actions: DELL stock is trading lower by 3.57% to $107.35 at last check Monday.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/05/45703385/dell-wins-wall-street-praise-after-12-billion-ai-server-orders-solid-commercial-pc-demand" target="_blank" rel="noreferrer noopener">Dell Wins Wall Street Praise After $12 Billion AI Server Orders, Solid Commercial PC Demand</a></li>
</ul>
Photo: mrinalpal / Shutterstock.com

Large Cap

Media

DELL

Dell Stock Falls As Trump Administration Expands Spending Review To Tech Contracts

MSGM

Motorsport Games shares are trading lower after the company announced it filed a prospectus to sell 2.3 million shares of its Class A common stock by selling stockholders.

WETO

Webus International Shares Halted On Circuit Breaker To The Downside, Stock Now Down -21%

Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) has outperformed the market over the past 20 years by 28.76% on an annualized basis producing an average annual return of 37.02%. Currently, Netflix has a market capitalization of $517.66 billion. 
Buying $1000 In NFLX: If an investor had bought $1000 of NFLX stock 20 years ago, it would be worth $573,001.38 today based on a price of $1216.40 for NFLX at the time of writing.
<h3>Netflix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748878213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NFLX

Here's How Much $1000 Invested In Netflix 20 Years Ago Would Be Worth Today

RSLS

ReShape Lifesciences shares are trading lower after the company announced it entered into an equity distribution agremeent relating to the sale of up to $9.7 million of shares of its common stock.

In a meeting in the corporate assembly of Equinor ASA ((OSE:EQNR, NYSE:<a href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) on 2 June 2025 Dawn Summers was elected as a new member of the board of directors of Equinor ASA.
The corporate assembly re-elected Jon Erik Reinhardsen as chair and Anne Drinkwater as deputy chair of the board, in addition to re-election of Finn Bjørn Ruyter, Haakon Bruun-Hanssen, Mikael Karlsson, Fernanda Lopes Larsen and Tone Hegland Bachke as members of the board of directors. The current member, Jonathan Lewis will resign from the board of directors as of 30 June 2025. Dawn Summers is elected as a new member of the board of directors of Equinor ASA.
The election of the shareholder representatives to the board of directors of Equinor ASA enters into effect from 1 July 2025, with the exception of Dawn Summers who is elected with effect from 1 September 2025, all with effect until the ordinary election of shareholder-representatives to the board of directors in June 2026.
Further, the corporate assembly re-elected Hilde Møllerstad, as employee-representative and elected Frank Indreland Gundersen and Geir Leon Vadheim as new employee-representatives of the board of directors of Equinor ASA. Also, Anette Heggholmen, Terje Werner Hansen and Hans Einar Haldorsen were elected as deputy members for the employee-representatives of the board.
The election of employee-representative members to the board of directors enters into effect from 1 July 2025 and is effective until the ordinary election of employee-representatives to the board of directors in 2027.

Management

EQNR

Equinor Re-Elects Erik Reinhardsen As Chair And Anne Drinkwater As Deputy Chair Of The Board

LUCD

Lucid Diagnostics shares are trading lower after the company announced a $25 million offering.

RVYL

Ryvyl Shares Halted On Circuit Breaker To The Upside, Stock Now Up 164.5%

KIDZ

Classover Holdings shares are trading higher after the company announced it entered into a securities purchase agreement with Solana Growth Ventures for the issuance of up to $500 million in senior secured convertible notes.

JMP Securities analyst Silvan Tuerkcan reiterates Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Market Outperform and maintains $6 price target.

NUVB

JMP Securities Reiterates Market Outperform on Nuvation Bio, Maintains $6 Price Target

JMP Securities analyst Roy Buchanan reiterates Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Market Outperform and maintains $47 price target.

CDTX

JMP Securities Reiterates Market Outperform on Cidara Therapeutics, Maintains $47 Price Target

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and raises the price target from $26 to $29.

APLS

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Raises Price Target to $29

Wells Fargo analyst Edward Kelly maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Overweight and raises the price target from $90 to $105.

Wells Fargo Maintains Overweight on Dollar Tree, Raises Price Target to $105

JMP Securities analyst Mitch Germain reiterates Broadstone Net Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNL#NYSE">BNL</a>) with a Market Outperform and maintains $21 price target.

JMP Securities Reiterates Market Outperform on Broadstone Net Lease, Maintains $21 Price Target

<ul>
<li>Relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection</li>
<li>Addition of relacorilant did not increase side-effects, compared to nab-paclitaxel monotherapy</li>
<li>Results presented in late-breaking podium presentation at ASCO 2025 with simultaneous publication in The Lancet</li>
</ul>
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer in a late-breaking oral presentation at the ASCO 2025 (American Society of Clinical Oncology) Annual Meeting.
The presentation abstract can be found <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmeetings.asco.org%2Fabstracts-presentations%2F243880&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=39fc98b20cea82363bf0c1ee891d18a4">here</a> and the presentation slides <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcorcept.com%2Frosella-data-asco-2025%2F&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=d027378ea105f9965e68b33374254744">here</a>. The data have been simultaneously published in The Lancet, titled "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%252825%252901040-2%2Ffulltext&amp;esheet=54262324&amp;newsitemid=20250602291571&amp;lan=en-US&amp;anchor=Relacorilant+and+nab-paclitaxel+in+patients+with+platinum-resistant+ovarian+cancer+%28ROSELLA%29%3A+an+open-label%2C+randomised%2C+controlled%2C+phase+3+trial&amp;index=3&amp;md5=9d1728b37a7ce57af0fea2a9f7d8fcd5">Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial</a>."
ROSELLA met its primary endpoint of improved progression-free survival as assessed by blinded independent central review (PFS-BICR). Patients who received relacorilant in addition to nab-paclitaxel chemotherapy experienced a 30 percent reduction in risk of disease progression compared to patients who received nab-paclitaxel monotherapy (hazard ratio: 0.70; p-value: 0.0076). Median PFS-BICR was extended to 6.5 months, compared to 5.5 months in patients who received nab-paclitaxel alone. In addition, PFS assessed by investigators was consistent with PFS-BICR, with a hazard ratio of 0.71 (p-value: 0.0030). An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients' lives. Median OS for patients who received relacorilant was 16.0 months, compared to 11.5 months for patients who received nab-paclitaxel alone (hazard ratio: 0.69; p-value: 0.0121). These benefits were seen in all clinically relevant subgroups, including those with poor prognoses.
Relacorilant plus nab-paclitaxel was well-tolerated, with a comparable safety profile between treatment arms. The addition of relacorilant did not increase patients' safety burden. In addition, patients treated with relacorilant plus nab-paclitaxel had a lower incidence of ascites (5.3 percent), than did patients who received nab-paclitaxel alone (10.5 percent). The occurrence of abdominal paracenteses during treatment was also lower for patients treated with relacorilant plus nab-paclitaxel (7.4 percent), compared to nab-paclitaxel alone (13.2 percent).

Biotech

General

CORT

Corcept Therapeutics Reports Phase 3 ROSELLA Trial Results As Relacorilant Plus Nab-Paclitaxel Improves Survival In Platinum-Resistant Ovarian Cancer Without Added Side Effects, Showing 30% Reduced Progression Risk And 31% Lower Death Risk In ASCO 2025 Late-Breaker And Simultaneous Lancet Publication

Wells Fargo analyst Chris Carey maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Equal-Weight and lowers the price target from $27 to $23.

Wells Fargo Maintains Equal-Weight on Conagra Brands, Lowers Price Target to $23

Press Releases

ESS Tech, Inc. Announces Third Quarter 2024 Financial Results

ESS Celebrates Commercial Launch of Energy Center™ Product

ESS Announces Actions to Position the Company for the Future

ESS Global Fleet Achieves Operational Milestone Surpassing 2 GWh of Transacted Energy

ESS Schedules Fourth Quarter and Full Year 2024 Financial Results Conference Call

ESS Tech, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

ESS Recognized as TIME Top GreenTech Company and one of Fortune's Most Innovative Companies in America for 2025

ESS Schedules First Quarter 2025 Financial Results Conference Call

ESS Tech, Inc. Announces First Quarter 2025 Financial Results

ESS Confirms Path to Continued Execution of its Strategic Plan with the Energy Base

Advent Technologies Holdings, Inc. - Class A Common Stock

Advent Technologies Hldgs

Asia Pacific Wire & Cable Corporation Limited - Common shares, Par value .01 per share

Comments

ESS Tech

뉴스

에 대한 최신 뉴스 ESS Tech (NYSE:GWH) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌